Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.
Portfolio Pulse from
Teva Pharmaceuticals and Alvotech have announced the U.S. availability of SELARSDI™ (ustekinumab-aekn), a biosimilar to Stelara®, for various conditions. The FDA has provisionally determined it will be interchangeable with Stelara® after April 30, 2025.
February 21, 2025 | 11:15 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Alvotech, in collaboration with Teva, has introduced SELARSDI™, a biosimilar to Stelara®, in the U.S. This could enhance Alvotech's presence in the U.S. biosimilar market.
The introduction of SELARSDI™ in the U.S. market is a significant step for Alvotech, potentially increasing its market share and visibility in the biosimilar sector.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Teva Pharmaceuticals, in partnership with Alvotech, has launched SELARSDI™, a biosimilar to Stelara®, in the U.S. This move could enhance Teva's market position in the biosimilar space.
The launch of SELARSDI™ strengthens Teva's biosimilar portfolio, potentially increasing its market share and revenue in the U.S. biosimilar market.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80